Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vivo

Journal of Dairy Science

Volumn 95, Issue 1, 2012, Pages 63-74

  Chen, Y P ^a   Hsiao, P J ^b   Hong, W S ^a   Dai, T Y ^a   Chen, M J ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Experimental colitis; Intestinal epithelial cell; Kefir; Probiotic

Indexed keywords

CYTOKINE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL STRAIN CACO 2; CELL STRAIN HEK293; COLITIS; DAIRY PRODUCT; DISEASE MODEL; DRUG EFFECT; FEMALE; HUMAN; INTESTINE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; LACTOBACILLUS; METABOLISM; MICROBIOLOGY; MOUSE; ORGAN CULTURE TECHNIQUE; PATHOLOGY; REPORTER GENE;

ANIMALS; CACO-2 CELLS; COLITIS; CULTURED MILK PRODUCTS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENES, REPORTER; HEK293 CELLS; HUMANS; INTESTINAL MUCOSA; INTESTINES; LACTOBACILLUS; MICE; MICE, INBRED C57BL; ORGAN CULTURE TECHNIQUES;

EID: 84055192823     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2011-4696     Document Type: Article

References (57)

1. Agle K.A., Vongsa R.A., Dwinell M.B. Calcium mobilization triggered by the chemokine CXCL12 regulates migration in wounded intestinal epithelial monolayers. J. Biol. Chem. 2010, 285:16066-16075.
2. Anderson R.C., Cookson A.L., McNabb W.C., Kelly W.J., Roy N.C. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol. Lett. 2010, 309:184-192.
3. Araki Y., Sugihara H., Hattori T. In vitro effects of dextran sulfate sodium on a Caco-2 cell line and plausible mechanisms for dextran sulfate sodium-induced colitis. Oncol. Rep. 2006, 16:1357-1362.
4. Caballero-Franco C., Keller K., De S.C., Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G315-G322.
5. Cai S., Bay B.H., Lee Y.K., Lu J., Mahendran R. Live and lyophilized Lactobacillus species elicit differential immunomodulatory effects on immune cells. FEMS Microbiol. Lett. 2010, 302:189-196.
6. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004, 127:224-238.
7. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132:1359-1374.
8. Castagliuolo I., Galeazzi F., Ferrari S., Elli M., Brun P., Cavaggioni A., Tormen D., Sturniolo G.C., Morelli L., Palù G. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol. Med. Microbiol. 2005, 43:197-204.
9. Chen H.C., Wang S.Y., Chen M.J. Microbiological study of lactic acid bacteria in kefir grains by culture-dependent and culture-independent methods. Food Microbiol. 2008, 25:492-501.
10. Chen L.L., Wamg X.H., Lian G.H., Zhang J., Ouyang C.H., Lu F.G. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J. Gastroenterol. 2009, 15:321-327.
11. Fajdiga S., Koninkx J.F.J.G., Tooten P.C.J., Marnšek-Logar R. Interference of Salmonella enteritidis and Lactobacillus spp. with IL-8 levels and transepithelial electrical resistance of enterocyte-like Caco-2 cells. Folia Microbiol. (Praha) 2006, 51:268-272.
12. Farnworth E.R., Mainville I. Kefir: A fermented milk product. Handbook of Fermented Functional Foods 2003, CRC Press, Boca Raton, FL, Pages 77-111.
13. Fitzpatrick L.R., Small J., Hoerr R.A., Bostwick E.F., Maines L., Koltun W.A. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: Immunomodulation and attenuation of murine colitis. Br. J. Nutr. 2008, 100:530-541.
14. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:503-514.
15. Geier M.S., Butler R.N., Howarth G.S. Inflammatory bowel disease: Current insights into pathogenesis and new therapeutic options: Probiotics, prebiotics and synbiotics. Int. J. Food Microbiol. 2007, 115:1-11.
16. Gibson D.L., Ma C., Rosenberger C.M., Bergstrom K.S.B., Valdez Y., Huang J.T., Khan M.A., Vallance B.A. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell. Microbiol. 2008, 10:388-403.
17. Herías M.V., Koninkx J.F.J.G., Vos J.G., Huis in't Veld J.H.J., van Dijk J.E. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int. J. Food Microbiol. 2005, 103:143-155.
18. Hoarau C., Martin L., Faugaret D., Baron C., Dauba A., Aubert-Jacquin C., Velge-Roussel F., Lebranchu Y. Supernatant from Bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS ONE 2008, 3:e2753.
19. Hong W.S., Chen H.C., Chen Y.P., Chen M.J. Effects of kefir supernant and lactic acid bacteria isolated from kefir grain on cytokine production by macrophage. Int. Dairy J. 2009, 19:244-251.
20. Johnson-Henry K.C., Donato K.A., Shen-Tu G., Gordanpour M., Sherman P.M. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect. Immun. 2008, 76:1340-1348.
21. Kaji R., Kiyoshima-Shibata J., Nagaoka M., Nanno M., Shida K. Bacterial teichoic acids reserve predominant IL-12 production induced by certain Lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J. Immunol. 2010, 184:3505-3513.
22. Karczewski J., Troost F.J., Konings I., Dekker J., Kleerebezem M., Brummer R.-J.M., Wells J.M. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G851-G859.
23. Klingberg T.D., Pedersen M.H., Cencič A., Budde B.B. Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Appl. Environ. Microbiol. 2005, 71:7528-7530.
24. Kojouharoff G., Hans W., Obermeier F., Männel D.N., Andus T., Schölmerich J., Gross V., Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 1997, 107:353-358.
25. Koninkx J.F.J.G., Tooten P.C.J., Malago G.G. Probiotic bacteria induced improvement of the mucosal integrity of enterocyte-like Caco-2 cells after exposure to Salmonella enteritidis 857. Funct. Foods 2010, 2:225-234.
26. Li N., DeMarco V.G., West C.M., Neu J. Glutamine supports recovery from loss of transepithelial resitance and increase of permeability induced by media change in Caco-2 cells. J. Nutr. Biochem. 2003, 14:401-408.
27. Liu J.R., Chen M.J., Lin C.W. Antimutagenic and antioxidant properties of milk-kefir and soymilk-kefir. J. Agric. Food Chem. 2005, 53:2467-2474.
28. Liu J.R., Wang S.Y., Chen M.J., Chen H.L., Yueh P.Y., Lin C.W. Hypocholesterolaemic effects of milk-kefir and soyamilk-kefir in cholesterol-fed hamsters. Br. J. Nutr. 2006, 95:939-946.
29. Liu J.R., Wang S.Y., Lin Y.Y., Lin C.W. Antitumor activity of milk kefir and soy milk kefir in tumor-bearing mice. Nutr. Cancer 2002, 44:183-187.
30. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
31. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.M., Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116:1107-1114.
32. Marchiando A.M., Graham W.V., Turner J.R. Epithelial barriers in homeostasis and disease. Annu. Rev. Pathol. 2010, 5:119-144.
33. Meng G., Rutz M., Schiemann M., Metzger J., Grabiec A., Schwandner R., Luppa P.B., Ebel F., Busch D.H., Bauer S., Wagner H., Kirschning C.J. Antagonistic antibody prevent toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 2004, 113:1473-1481.
34. Mileti E., Matteoli G., Iliev L.D., Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of lactobacilli using complex culture systems: Prediction for in vivo efficacy. PLoS ONE 2009, 4:e7056.
35. Miyauchi E., Morita H., Tanabe S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J. Dairy Sci. 2009, 92:2400-2408.
36. Nanda Kumar N.S.N., Balamurugan R., Jayakanthan K., Pulimood A., Pugazhendhi S., Ramakrishna B.S. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J. Gastroenterol. Hepatol. 2008, 23:1834-1839.
37. Neish A.S. Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflamm. Bowel Dis. 2004, 10:159-168.
38. Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: Recent advances. Inflamm. Bowel Dis. 2009, 15:300-310.
39. Obermeier F., Kojouharoff G., Hans W., Scholmerich J., Gross V., Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 1999, 116:238-245.
40. Pronio A., Montesani C., Butteroni C., Vecchione S., Mumolo G., Vestri A., Vitolo D., Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 2008, 14:662-668.
41. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
42. Reiff C., Delday M., Rucklidge G., Reid M., Duncan G., Wohlgemuth S., Hormannsperger G., Loh G., Blaut M., Collie-Duguid E., Haller D., Kelly D. Balancing inflammatory, lipid and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowe disease. Inflamm. Bowel Dis. 2009, 15:1721-1736.
43. Reiff C., Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int. J. Med. Microbiol. 2010, 300:25-33.
44. Resta-Lenert S., Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003, 52:988-997.
45. Resta-Lenert S., Barrett K.E. Probiotics and commensals reverse TNF-α- and IFN-γ-induced dysfunction in human intestinal epithelial cells. Gastroenterology 2006, 130:731-746.
46. Schlee M., Harder J., Koten B., Stange E.F., Wehkamp J., Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin. Exp. Immunol. 2008, 151:528-535.
47. Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S.C., Goulet J., Tompkins T.A. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7 and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun. 2005, 73:5183-5188.
48. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20:495-549.
49. Struyf S., Gouwy M., Dillen C., Proost P., Opdenakker G., Damme J.V. Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. Eur. J. Immunol. 2005, 32:1583-1591.
50. Ukena S.N., Singh A., Dringenberg U., Engelhardt R., Seidler U., Hansen W., Bleich A., Bruder D., Franzke A., Rogler G., Suerbaum S., Buer J., Gunzer F., Westendorf A.M. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2007, 2:e1308.
51. Ulisse S., Gionchetti P., D'Alò S., Russo F.P., Pesce I., Ricci G., Rizzello F., Helwig U., Cifone M.G., Campieri M., De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. Am. J. Gastroenterol. 2001, 96:2691-2699.
52. Vanderpool C., Yan F., Polk B. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14:1585-1596.
53. Voltan S., Castagliuolo I., Elli M., Longo S., Brun P., D'Incà R., Porzionato A., Macchi V., Palù G., Sturniolo G.C., Morelli L., Martines D. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin. Vaccine Immunol. 2007, 14:1138-1148.
54. 2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-γ in the intestinal mucosa. Gastroenterology 2008, 135:1216-1227.
55. Vongsa R.A., Zimmerman N.P., Dwinell M.B. CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J. Biol. Chem. 2009, 284:10034-10045.
56. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2:541-546.
57. Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCζ redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 2007, 9:804-816.